iShares U.S. Medical Devices ETF (ARCA: IHI)

最新ニュース iShares U.S. Medical Devices ETF (ARCA:IHI)

iShares U.S. Medical Devices ETF

Healthcare

The Fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index; the Underlying Index, which measures the performance of the medical equipment sector of the U.S. equity market, as defined by S&P Dow Jones Indices LLC; the Index Provider or SPDJI.

Abbott Laboratories

Intuitive Surgical Inc

Stryker Corp

Boston Scientific Corp.

Ge Healthcare Technologies Inc

Becton Dickinson And Co.

Medtronic Inc

Idexx Labs

Resmed Inc.

Edwards Lifesciences Corp

iShares US Medical Devices ETF

IHI Corp

ISHARES III IRE USD ORD by Ishares III Plc

ISHARES II PLC EUR 50 ORD by iShares II plc.

Invesco High Income 2023 Target Term Fund Com

Robert F. Kennedy Jr.&#8216;s appointment as U.S. Secretary of Health and Human Services has sparked concerns over funding for the National Institutes of Health. Analysts warn that potential cuts to this funding could lead to increased &#8220;uncertainty&#8221; in the healthcare sector, potentially impacting healthcare stocks.
What Happened: The NIH grants are &#8220;very important&#8221; sources of funding for a lot of labs out there, said Kyle Mikson, managing director and senior research analyst in <a href="https://www.buzzsprout.com/2414939/episodes/16662667">conversation</a> with Michael Graham, senior managing director and head of U.S. equity research internet analyst at Canaccord Genuity. 
Talking about RFK Jr.&#8217;s appointment Mikson said &#8220;He&#8217;s got some opposition to vaccines, to infectious disease research.&#8221; Highlighting the possible funding cuts along with caps on grants, Mikson added, "Things like that are causing uncertainty, causing, you know, stocks to decline."
Kennedy, known for his vaccine skepticism and conspiracy theories, has extended his influence globally, undermining health initiatives like vaccination and AIDS prevention, The New York Times <a href="https://www.nytimes.com/2024/11/30/world/africa/rfk-jr-kennedy-international-work-public-health-policies.html">reports</a>. Through his nonprofit, Children's Health Defense, Kennedy has <a href="https://www.benzinga.com/markets/equities/24/11/42254495/trumps-hhs-pick-rfk-jr-has-a-long-history-of-challenging-global-health-policies">disrupted public health efforts</a> in countries like Uganda and South Africa. He has also questioned the World Health Organization and its programs for fueling global health conspiracies.
The Donald Trump-led <a href="https://www.benzinga.com/general/health-care/25/01/43194764/trump-administration-halts-all-communications-from-the-centers-for-disease-control-as-bird-flu-spreads">administration</a> is trying to set caps at around 15% and 10% for some labs which is delayed due to broad opposition by many states. While this is detrimental to some NIH-funded labs, others have stated that they can function without indirect cost funding or support.
While, NIH awarded about $2.5 billion in grants in the first six weeks of 2024, this year, that number has plummeted to $1.4 billion.
See Also: <a href="https://www.benzinga.com/25/02/43906366/warren-buffetts-berkshire-boosts-bets-on-five-japanese-companies-admiration-has-consistently-grown-says-oracle-of-omaha-in-letter-to-shareholders">Warren Buffett&#8217;s Berkshire Boosts Bets On 5 Japanese Companies: Oracle Of Omaha Says Admiration &#8216;Has Consistently Grown&#8217;</a>
Why It Matters: While there isn't going to be a blanket impact of these caps on all healthcare firms, Mikson explains that companies that are academically focused are more likely to be impacted as compared to the ones with a mixed revenue base.
However, when considering investment opportunities, especially for growth-oriented companies with research-driven businesses, the impact is particularly important, Mikson explained.
According to the <a href="https://www.benzinga.com/markets/equities/25/02/43878703/institutional-investors-load-up-on-technology-and-financial-stocks-in-q4-while-reducing-positions-in-healthcare-sector-amid-political-uncertainty">13F SEC filings</a> during the fourth quarter, healthcare sectors experienced a sharp decline in investments, with allocations dropping by 1.4%. Adam Turnquist, the chief technical strategist at LPL Financial said that "The nomination of the so-called anti-vaccine Health Secretary, Robert F. Kennedy, Jr., and the potential for reduced Affordable Care Act subsidies," was also a potential trigger.
Kennedy&#8217;s appointment comes as healthcare costs rise and <a href="https://www.benzinga.com/general/health-care/25/02/43549057/deadly-bird-flu-strain-hits-dairy-cows-could-make-covid-seem-like-a-walk-in-the-park-expert-says">bird flu spreads</a>, raising pandemic concerns. A longtime vaccine skeptic, his stance could impact pharmaceutical companies like Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), especially as he has questioned the safety and efficacy of bird flu vaccines.
Here is a list of healthcare sector-linked exchange-traded funds, that investors could consider while trying to gain exposure to the sector.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>ETF Name</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>6.41%</td>
<td>-0.46%</td>
</tr>
<tr>
<td>Vanguard Health Care ETF VHT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHT#NYSE">VHT</a>)</td>
<td>5.79%</td>
<td>-0.19%</td>
</tr>
<tr>
<td>iShares Biotechnology ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBB#NASDAQ">IBB</a>)</td>
<td>4.51%</td>
<td>-0.18%</td>
</tr>
<tr>
<td>SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>)</td>
<td>0.19%</td>
<td>-5.79%</td>
</tr>
<tr>
<td>iShares U.S. Medical Devices ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHI#NYSE">IHI</a>)</td>
<td>10.36%</td>
<td>12.22%</td>
</tr>
<tr>
<td>iShares Global Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IXJ#NYSE">IXJ</a>)</td>
<td>6.67%</td>
<td>-0.57%</td>
</tr>
<tr>
<td>iShares U.S. Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYH#NYSE">IYH</a>)</td>
<td>5.52%</td>
<td>-0.26%</td>
</tr>
<tr>
<td>Fidelity MSCI Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHLC#NYSE">FHLC</a>)</td>
<td>5.90%</td>
<td>-0.27%</td>
</tr>
<tr>
<td>ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)</td>
<td>10.14%</td>
<td>-14.26%</td>
</tr>
<tr>
<td>First Trust NYSE Arca Biotechnology Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBT#NYSE">FBT</a>)</td>
<td>6.72%</td>
<td>16.97%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43878703/institutional-investors-load-up-on-technology-and-financial-stocks-in-q4-while-reducing-positions-in-healthcare-sector-amid-political-uncertainty">Institutional Investors Load Up On Technology And Financial Stocks In Q4 While Reducing Positions In Healthcare Sector Amid Political Uncertainty</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Equities

Government

Market Summary

News

Regulations

Markets

ETFs

General

ARKG

First Trust NYSE Arca Biotechnology Index Fund

FHLC

iShares Dow Jones US Medical Devices Index Fund

iShares Trust S&P Global Healthcare Sector Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

MRNA

NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst

DeepSeek&#8217;s breakthrough AI model has kept the AI industry buzzing these past two weeks, sending stocks of big names in tech plummeting. However, there is one sector that leverages AI but is not susceptible to its volatility, and that<a href="https://www.benzinga.com/general/health-care"> is healthcare tech.</a>
Health care tech benefits from advancements in AI while sidestepping the megacap tech names that often dominate portfolios. Plus, valuations in health care have relaxed, adding to the positives. Here are three <a href="https://www.benzinga.com/etfs">ETFs that stand out</a>, avoiding concentration risk while providing exposure to cutting-edge tech:
ROBO Global Healthcare Technology and Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTEC#NYSE">HTEC</a>): This ETF charges 68 basis points in fees and covers a broad range of industries, including regenerative medicine, lab process automation, and telehealth.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43340327/meta-vs-microsoft-can-their-ai-infrastructure-plans-hold-up-against-deepseek">Meta Vs. Microsoft: Can Their AI Infrastructure Plans Hold Up Against DeepSeek?</a>
Global X Telemedicine &amp; Digital Health ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDOC#NASDAQ">EDOC</a>) offers another way to capitalize on the rapid digital transformation in health care. As the demand for telehealth, AI-driven diagnostics, and remote patient monitoring accelerates, this ETF provides targeted exposure. 
According to Precedence Research, the global health care IT market is expected to be valued at $880.56 billion in 2025 and is expected to reach $3.3 trillion by 2034, witnessing a CAGR of 15.83%. EDOC's holdings include firms developing AI-powered radiology tools, medical imaging solutions, and drug discovery platforms.
Moreover, the ETF stands to benefit from the increased adoption of natural language processing (NLP) systems, an AI innovation that enhances doctor-patient interactions and streamlines administrative workflows. These innovations help reduce paperwork and improve efficiency, which are key factors driving industry-wide growth.
iShares U.S. Medical Devices ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IHI#NASDAQ">IHI</a>) is best suited for investors looking for a more hardware-focused approach. This ETF offers exposure to leading medical technology companies. This ETF targets firms specializing in robotic-assisted surgery, diagnostic imaging, and medical instruments. 
As of early 2025, the U.S. health care technology management market is projected to reach $17.3 billion by 2028, growing at a robust CAGR of 15.6%, per Markets and Markets.
This ETF also carries an expense ratio of 0.68%, and is well-positioned to benefit from AI's role in surgical precision, automation, and predictive analytics.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43346788/telecom-etfs-gain-momentum-as-sector-delivers-strong-q4-earnings">Telecom ETFs Gain Momentum As Sector Giants AT&amp;T, Verizon, T-Mobile Reinforce Investor Confidence</a></li>
</ul>
Photo: raker/Shutterstock.com

Sector ETFs

EDOC

HTEC

DeepSeek Shakes Up AI Stocks: 3 Healthcare Tech ETFs Offer Stability, Innovation

Stryker Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) shares are trading <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">marginally lower on Wednesday.</a>
The company announced the addition of two new products to its Foot &amp; Ankle portfolio – the Osteotomy Truss System and Ankle Truss System, recently <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40812066/stryker-expands-foot-ankle-portfolio-with-specialized-offerings-designed-to-enhance-surgical-preci" rel="noreferrer noopener">acquired from 4WEB Medical</a>.
The new Ankle Truss System, featuring Arthrosphere and Arthrocube implants, is a groundbreaking solution for restoring limb length and ensuring structural stability during tibiotalocalcaneal fusions.
&#8220;The addition of the ATS and the integration of Artelon reflects our commitment to providing surgeons with enhanced orthopaedic solutions to achieve the best possible patient outcomes,&#8221; said Michael Rankin, vice president of marketing and medical education of Stryker&#8217;s Foot &amp; Ankle business.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40771038/summit-therapeutics-lung-cancer-candidate-surpasses-mercks-multi-billion-dollar-keytruda-cuts-ris" rel="noreferrer noopener">Summit Therapeutics&#8217; Lung Cancer Candidate Surpasses Merck&#8217;s Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half</a>
Utilizing Truss Implant Technology, the ATS implants have an open architecture designed to deliver robust support and facilitate successful fusion.
The Osteotomy Truss System includes Cotton, Evans, and Utility wedges, providing a complete solution for various osteotomy procedures. Designed for internal bone fixation and osteotomies in the foot and ankle, this system is now available for clinical use.
Yesterday, Piper Sandler analyst Matt O&#8217;Brien maintained Stryker with an Overweight rating and a $380&nbsp;price target.
In addition, Wolfe Research analyst Mike Polark initiates coverage on Stryker with an Outperform rating and announces a $405 price forecast.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, SYK stock has gained over 10% in 2023. Investors can gain exposure to the stock via iShares U.S. Medical Devices ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHI#NYSE">IHI</a>) and&nbsp;Trust for Professional Managers Jensen Quality Growth ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JGRW#NYSE">JGRW</a>).
Price Action: SYK shares are trading lower by 0.22% to $364.25 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40754517/modernas-investigational-mpox-vaccine-more-effective-than-current-approved-shot-animal-study-show" target="_blank" rel="noreferrer noopener">Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows</a>.</li>
</ul>

Health Care

Analyst Ratings

Trust for Professional Managers Jensen Quality Growth ETF

JGRW

Stryker Unveils New Foot & Ankle Solutions With Truss Implants: Details

On CNBC's <a href="https://www.cnbc.com/video/2024/08/29/final-trades-cme-group-chubb-berkshire-hathaway-and-the-ihi.html">&#8220;Halftime Report Final Trades</a>,&#8221; Kevin Simpson of Capital Wealth Planning said CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) yields a 4.5% dividend and trades at a forward PE of 21, which is pretty low. The company has a free cash <a href="https://www.benzinga.com/quote/CME/analyst-ratings">flow of $3.5 billion.</a>
On Aug. 2, CME Group reported its July market statistics set a new July average daily volume (ADV) record of 24.8 million contracts, up 24% from the year-ago month.
Bill Baruch of Blue Line Capital said Chubb Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) is the best in breed. Warren Buffett is a big fan of that stock.
On July 23, Chubb posted better-than-expected second-quarter earnings. The company reported quarterly earnings of $5.38 per share which beat the analyst consensus estimate of $5.15. The company reported quarterly sales of $11.780 billion which beat the analyst consensus estimate of $11.642 billion.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage her</a>e
Joshua Brown of Ritholtz Wealth Management said Berkshire Hathaway Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) continues to move higher.
On July 22, TD Cowen analyst Andrew Kilgerman initiated coverage on Berkshire Hathaway with a Hold rating and announced a price target of $465.
Liz Young of SoFi named iShares U.S. Medical Devices ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHI#NYSE">IHI</a>) as her final trade.
Price Action:
<ul>
<li>CME Group shares fell 0.5% to close at $214.10 during Thursday's session.</li>
<li>Chubb shares gained 1.2% to settle at $281.98 during Thursday's session.</li>
<li>Berkshire Hathaway shares gained 0.8% to settle at $468.37 on Thursday.</li>
<li>iShares U.S. Medical Devices ETF rose 0.5% during Thursday's session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/24/08/40624754/top-2-materials-stocks-that-are-ticking-portfolio-bombs">Top 2 Materials Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Long Ideas

Media

Trading Ideas

CME Group, Chubb, Berkshire Hathaway And More On CNBC's 'Final Trades'

BRK/B

CNBC Halftime Report Final Trades: CME Group, Chubb, Berkshire Hathaway Inc. New Common Stock, iShares U.S. Medical Devices ETF

As April comes to a close, it&#8217;s time to compile the rankings for the top-performing sector and industry exchange-traded <a href="https://www.benzinga.com/etfs">funds of the month.</a>
Taking a broader look at the stock market, the S&amp;P 500 Index, represented by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), finished April on a downturn, declining by approximately 3%. This marks the end of a five-month streak of gains.
Similarly, the tech-heavy Nasdaq 100, tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), experienced a 3.5% decline.
Among large-cap indices, blue-chip stocks showed slight underperformance, with the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) slipping by 4.5%.
Small-cap stocks, represented by the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), plummeted by over 6%, marking their worst performance since October 2023.
Overall, it has been a challenging month for the stock market, primarily due to inflation surprises surpassing expectations. This has led to a recalibration of market expectations regarding potential Federal Reserve rate cuts.
Additionally, complex global geopolitical tensions have emerged, notably between Israel and Iran, alongside the ongoing issue in the Gaza Strip.
May is anticipated to start with a crucial event as investors await the Federal Reserve Open Market Committee <a href="https://www.benzinga.com/general/macro-notification/24/04/38526201/is-hawkish-shift-on-inflation-imminent-wall-street-analysts-traders-brace-for-fed-impa">(FOMC) meeting on Wednesday. </a>
While no interest rate changes are expected, all eyes will be on Fed Chair Jerome Powell&#8216;s remarks to assess the Fed&#8217;s stance in response to recent inflation surprises.
Read also: <a href="https://www.benzinga.com/general/macro-notification/24/04/38491988/federal-reserve-meeting-preview-high-interest-rates-need-more-time-to-work-bank-of-ame">Federal Reserve Meeting Preview: High Interest Rates &#8216;Need More Time To Work,&#8217; Bank of America Says</a>
<h2 class="wp-block-heading">Performance Of Sector ETFs In April 2024</h2>
At the sector level, only the utilities sector managed to avoid losses for the month, rising by 2.1%.
The largest stock contributors to the utilities&#8217; performance in April are NextEra Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>), The Southern Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>), Dominion Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>) and NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) which showed monthly gains between 4% and 8%. 
Energy stocks remained broadly stable, while the other nine S&amp;P 500&#8217;s sectors showcased losses.
Real estate experienced the worst performance, down by over 7%, dragged down by its high sensitivity to interest rates, as Treasury yields increase across the board during the month. 
Following real estate, the technology and healthcare sectors also showed poor performance in April.
<h4 class="wp-block-heading">April&#8217;s Best And Worst Sector ETFs: Utilities Lead, Real Estate Lags</h4>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Sector</th>
<th>April 2024 performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>2.06%</td>
</tr>
<tr>
<td>Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>0.01%</td>
</tr>
<tr>
<td>Consumer Staples&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>-1.11%</td>
</tr>
<tr>
<td>Industrials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>-3.23%</td>
</tr>
<tr>
<td>Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>-3.68%</td>
</tr>
<tr>
<td>Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>-3.85%</td>
</tr>
<tr>
<td>Materials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>-4.13%</td>
</tr>
<tr>
<td>Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>-4.24%</td>
</tr>
<tr>
<td>Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>-4.78%</td>
</tr>
<tr>
<td>Health Care&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>-4.85%</td>
</tr>
<tr>
<td>Real Estate&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>-7.83%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data as of Apr. 30, 2024 2:50 p.m. EDT</figcaption></figure>
<h2 class="wp-block-heading">Performance Of Industry ETFs In April 2024</h2>
Based on the industry ETF list provided by BlackRock Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) iShares, only five out of the 25 industries managed to report gains in April. Among them, miners did well across the board, with silver, copper, and gold mining stocks reporting robust gains. 
Standout contributors to the mining industry&#8217;s outperformance in April were Pan American Silver Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>), up over 20%, Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), up 14%, Anglo American plc (OTCPK: AAUKF), up over 40%
Energy producers also managed to end the month in the green.
On the bottom side of the industry rankings, homebuilders, transportation, biotech stocks, digital infrastructure and real estate all report losses between 7% and 9.6% in April.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>ETF Name</th>
<th>Performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>iShares MSCI Global Silver and Metals Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLVP#NYSE">SLVP</a>)</td>
<td>12.11%</td>
</tr>
<tr>
<td>iShares Copper and Metals Mining ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COPX#NYSE">COPX</a>)</td>
<td>9.50%</td>
</tr>
<tr>
<td>iShares MSCI Global Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RING#NYSE">RING</a>)</td>
<td>5.93%</td>
</tr>
<tr>
<td>iShares MSCI Global Metals &amp; Mining Producers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PICK#NYSE">PICK</a>)</td>
<td>2.81%</td>
</tr>
<tr>
<td>iShares MSCI Global Energy Producers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FILL#NYSE">FILL</a>)</td>
<td>2.46%</td>
</tr>
<tr>
<td>iShares U.S. Aerospace &amp; Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITA#NYSE">ITA</a>)</td>
<td>-1.16%</td>
</tr>
<tr>
<td>iShares U.S. Oil &amp; Gas Exploration &amp; Production ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEO#NYSE">IEO</a>)</td>
<td>-1.37%</td>
</tr>
<tr>
<td>iShares Residential and Multisector Real Estate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REZ#NYSE">REZ</a>)</td>
<td>-1.66%</td>
</tr>
<tr>
<td>iShares Lithium Miners and Producers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ILIT#NYSE">ILIT</a>)</td>
<td>-3.30%</td>
</tr>
<tr>
<td>iShares U.S. Broker-Dealers &amp; Securities Exchange ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAI#NYSE">IAI</a>)</td>
<td>-3.74%</td>
</tr>
<tr>
<td>iShares U.S. Financial Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYG#NYSE">IYG</a>)</td>
<td>-3.88%</td>
</tr>
<tr>
<td>iShares Expanded Tech Sector ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGM#NYSE">IGM</a>)</td>
<td>-4.37%</td>
</tr>
<tr>
<td>iShares Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NYSE">SOXX</a>)</td>
<td>-4.40%</td>
</tr>
<tr>
<td>iShares U.S. Healthcare Providers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHF#NYSE">IHF</a>)</td>
<td>-4.79%</td>
</tr>
<tr>
<td>iShares U.S. Insurance ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAK#NYSE">IAK</a>)</td>
<td>-4.85%</td>
</tr>
<tr>
<td>iShares U.S. Regional Banks ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAT#NYSE">IAT</a>)</td>
<td>-5.11%</td>
</tr>
<tr>
<td>iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-5.38%</td>
</tr>
<tr>
<td>iShares U.S. Oil Equipment &amp; Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEZ#NYSE">IEZ</a>)</td>
<td>-5.45%</td>
</tr>
<tr>
<td>iShares Mortgage Real Estate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REM#NYSE">REM</a>)</td>
<td>-5.57%</td>
</tr>
<tr>
<td>iShares U.S. Medical Devices ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHI#NYSE">IHI</a>)</td>
<td>-5.75%</td>
</tr>
<tr>
<td>iShares Global Timber &amp; Forestry ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOOD#NYSE">WOOD</a>)</td>
<td>-6.20%</td>
</tr>
<tr>
<td>iShares Expanded Tech-Software Sector ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGV#NYSE">IGV</a>)</td>
<td>-6.76%</td>
</tr>
<tr>
<td>iShares U.S. Digital Infrastructure and Real Estate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDGT#NYSE">IDGT</a>)</td>
<td>-7.12%</td>
</tr>
<tr>
<td>iShares Biotechnology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBB#NYSE">IBB</a>)</td>
<td>-7.23%</td>
</tr>
<tr>
<td>iShares U.S. Transportation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYT#NYSE">IYT</a>)</td>
<td>-8.34%</td>
</tr>
<tr>
<td>iShares U.S. Home Construction ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITB#NYSE">ITB</a>)</td>
<td>-9.60%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data as of Apr. 30, 2024 3:15 p.m. EDT</figcaption></figure>
Now read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38497224/ai-data-centers-drive-electricity-demand-goldman-sachs-picks-16-stocks-to-play-the-">AI Data Centers Drive Electricity Demand: Goldman Sachs Picks 16 Stocks To Play The Trend</a>
Image generated using artificial intelligence via Midjourney.

Biotech

Large Cap

Mid Cap

REIT

Broad U.S. Equity ETFs

Specialty ETFs

Commodities

Small Cap

Econ #s

Federal Reserve

Tech

Real Estate

AAUKF

COPX

SPDR Dow Jones Industrial Average ETF Trust

FILL

iShares Dow Jones US Broker Dealers Index Fund

iShares Dow Jones US Insurance Index Fund

iShares Dow Jones US Regional Banks Index Fund

iShares U.S. Digital Infrastructure and Real Estate ETF

IDGT

iShares Dow Jones US Oil & Gas Exploration & Production Index Fund

iShares Dow Jones US Oil Equipment & Services Index Fund

iShares Dow Jones US Pharmaceuticals Index Fund

iShares Dow Jones US Health Care Provides Index Fund

ILIT

iShares Dow Jones US Aerospace & Defense Index Fund

iShares Dow Jones US Homenstruction Index Fund

iShares Trust Dow Jones US Financial Services Index Fund

iShares Dow Jones Transportation Average Index Fund

PAAS

PICK

iShares FTSE NAREIT Mortgage PLUS Capped Index Fund

iShares FTSE NAREIT Residential PLUS Capped Index Fund

RING

SLVP

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

iShares S&P Global Timber & Forestry Index Fund

WOOD

XLRE

Select Sector SPDR-Consumer Discretionary

April Showers On Wall Street:  Miners, Utilities Emerge As Bright Spots In Gloomy Market

Elon Musk&#8217;s <a href="https://www.benzinga.com/news/23/09/34792666/elon-musks-neuralink-begins-recruiting-quadraplegiacs-for-first-of-kind-human-trials-to-help-users-c">Neuralink </a>will likely collect sizeable revenue from its N1 brain implant in out years, according to an analyst at Ark Investment Management.
What Happened: If the N1 module and R1 surgical robot succeed in getting FDA approval for ALS, a neurodegenerative disorder that results in progressive degeneration of nerve cells in the spinal cord and brain, and cervical spinal cord injuries, there will likely be modest adoption by 2025, said Ark analyst Pierce Jamieson.
Neuralink&#8217;s N1 implant is cosmetically invisible and is intended to record and transmit brain signals wirelessly to an app that decodes movement intention.&nbsp;The R1 Robot will be used to surgically place the N1 Implant's ultra-fine and flexible threads in a region of the brain that controls movement intention.
Annual revenue for N1 devices alone could surpass $220 million by 2030, Jamieson said, citing the firm&#8217;s preliminary research.
See Also:<a href="https://www.benzinga.com/money/best-healthcare-stocks"> Best Healthcare Stocks To Buy Now</a>
Why It&#8217;s Important: Neuralink is developing brain-machine interfaces BMIs, that link the human brain with computers and build on the works of other technologies like deep brain stimulation, electrocorticography, and machine learning, Jamieson said. &#8220;Neuralink has significant potential to transform medicine and accelerate the link between humans and artificial intelligence,&#8221; he said.
The technology also could bypass spinal cord injuries and transmit brain signals directly to devices that help amputees regain mobility and control, the analyst said. Longer term, BMIs could treat ALS, Parkinson&#8217;s disease, epilepsy, sensory disorders, stroke-related brain injury, and many other conditions, he added.
In late May, Neuralink <a href="https://www.benzinga.com/news/23/05/32588521/elon-musks-brain-chip-company-gets-fda-greenlight-for-first-in-human-clinical-study">received FDA approval for commencing its first-in-human clinical trial.</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our…
&mdash; Neuralink (@neuralink) <a href="https://twitter.com/neuralink/status/1661857379460468736?ref_src=twsrc%5Etfw">May 25, 2023</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<figcaption class="wp-element-caption">Last month, the company said it had received approval from the independent institutional review board and its first hospital site to begin recruitment for the first-in-human study.</figcaption></figure>
The iShares U.S. Medical Devices ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHI#NYSE">IHI</a>) ended Tuesday&#8217;s session up 0.72% at $46.17, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">Benzinga Pro data.</a>
Read Next: <a href="https://www.benzinga.com/news/23/03/31591486/elon-musk-says-neuralink-is-the-only-way-to-survive-and-compete-with-ai">Elon Musk Says Neuralink Is The Only Way To Survive And Compete With AI</a>

Elon Musk-Owned Neuralink's Brain Implant Could Fetch Over $220M Revenue In ALS Patients By 2030, Says Ark Analyst

We performed a screening of medium-cap ETFs, defined as having Assets Under Management (AUM) between $2 billion and $10 billion &#8211; to determine what funds had the largest positive and negative returns on the week, according to data from <a href="http://etfdb.com">etfdb.com</a>. Only non-leveraged funds were considered.
<h2 class="wp-block-heading">Winners</h2>
SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOP#NYSE">XOP</a>)
XOP is up 6.53% over the trailing week.
The SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production ETF offers exposure to the exploration and production sub-sector of the domestic oil market. Like many of State Street's products, it is equal weighted, making it a balanced option.
The fund has $3.64 billion in AUM and an expense ratio of 0.35%. XOP has holdings in 60 companies, with the 10 largest comprising 25.60% of the fund.
The fund's largest holdings are Range Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) and Diamondback Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) making up 2.71% and 2.63% of the fund, respectively.
XOP is up 11.52% YTD.
VanEck Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDXJ#NYSE">GDXJ</a>)
GDXJ was up 6.47% on the week.
The VanEck Gold Miners ETF provides exposure to the gold mining industry. The performance of the underlying equities tends to correlate to the spot price of gold, making this a sort of indirect investment in gold itself, although this is not a one-to-one correlation.
GDXJ has $3.65 billion in AUM and an expense ratio of 0.52%. The fund has holdings in 94 companies, with the 94 largest comprising 43.53% of the fund.
The fund's largest holdings are Kinross Gold Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>) and Pan American Silver Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>) making up 6.94% and 6.64% of the fund, respectively.
YTD, GDXJ is down 4.94%.
<h2 class="wp-block-heading">Losers</h2>
iShares U.S. Medical Devices ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHI#NYSE">IHI</a>)
IHI is down 5.54% on the week.
The iShares U.S. Medical Devices ETF focuses on the oft-overlooked device section of the healthcare sector. Devices tend to be a more steady bet than pharmaceuticals as the approval pipeline tends to be less of a gamble.
IHI has $5.05 billion in AUM and an expense ratio of 0.40%. The fund has holdings in 56 companies, with the 10 largest comprising 71.84% of the fund. Its largest holdings are Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) and Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) making up 17.44% and 10.61%, respectively.&nbsp;
IHI is down 13.37%, YTD.
ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)
ARKK was down 3.67% on the week.
The ARK Innovation ETF is Cathie Wood's flagship ETF. The fund invests in "disruptive" companies defined as those companies that introduce a technologically enabled new product or service that potentially changes the way the world works.
ARKK has $7.00 billion in AUM and an expense ratio of 0.75%. The fund has holdings in 32 companies, with the 10 largest comprising 61.79% of the fund.
The fund's largest holdings are Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Coinbase Global, Inc. Class A (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) making up 10.35% and 8.00% of the fund, respectively.
YTD, ARKK is up 21.90%.
Featured photo by <a href="https://unsplash.com/@luandmario?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">Maria Lupan</a> on <a href="https://unsplash.com/photos/hy97yy3e03A?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">Unsplash</a>

ARKK

COIN

FANG

GDXJ

ISRG

TSLA

Amid Israel-Palestine And Ukraine Gas, Gold Up Big, Cathie Wood's ARKK Down Almost 4% - ETF Winners And Losers: Medium-Cap Returns

We performed a screening of medium-cap ETFs, defined as having Assets Under Management (AUM) between $2 billion and $10 billion &#8211; to determine what funds had the largest positive and negative returns on the week, according to data from <a href="http://etfdb.com">etfdb.com</a>. Only non-leveraged funds were considered.
VanEck Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDXJ#NYSE">GDXJ</a>)
GDXJ was up 8.24% on the week.
The VanEck Gold Miners ETF provides exposure to the gold mining industry. The performance of the underlying equities tends to correlate to the spot price of gold, making this a sort of indirect investment in gold itself, although this is not a one-to-one correlation.
GDXJ has $3.65 billion in AUM and an expense ratio of 0.52%. The fund has holdings in 53 companies, with the 94 largest comprising 43.53% of the fund.
The fund's largest holdings are Kinross Gold Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>) and Pan American Silver Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>) making up 6.74% and 6.73% of the fund, respectively.
YTD, GDXJ is down 6.40%.
KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>)
KWEB is up 8.03% on the week.
KraneShares CSI China Internet ETF offers pure-play exposure to Chinese software and information technology stocks. These companies directly compete with the FANG+ behemoths that dominate the US market.
KWEB has $5.54 billion in AUM and an expense ratio of 0.69%. The fund has holdings in 32 companies, with the 10 largest comprising 61.85% of the fund.
The fund's largest holdings are PDD Holdings Inc. Sponsored ADR Class A (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) and Alibaba Group Holding Limited (HKG: 9988) making up 10.44% and 8.75% of the fund, respectively.
YTD, KWEB is down 5.10%.
<h2 class="wp-block-heading">Losers</h2>
iShares U.S. Medical Devices ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHI#NYSE">IHI</a>)
DBC is down 2.83% on the week.
The iShares U.S. Medical Devices ETF focuses on the oft-overlooked device section of the healthcare sector. Devices tend to be a more steady bet than pharmaceuticals as the approval pipeline tends to be less of a gamble.
DBC has $5.05 billion in AUM and an expense ratio of 0.40%. The fund has holdings in 56 companies, with the 10 largest comprising 71.84% of the fund. Its largest holdings are Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) and Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) making up 17.40% and 10.72%, respectively.&nbsp;
DBC is down 11.43%, YTD.
Vanguard Consumer Staples ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VDC#NYSE">VDC</a>)
VDC is down 1.87% on the week.
The Vanguard Consumer Staples ETF offers exposure to one of the safest sectors of the US economy, consumer staples.
VDC has $6.36 billion in AUM and an expense ratio of 0.10%. The fund has holdings in 107 companies, with the 10 largest comprising 60.70% of the fund. Its largest holdings are Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) and Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) making up 12.61% and 8.24%, respectively.&nbsp;
VDC is down 5.70%, YTD.Featured photo by<a href="https://unsplash.com/@pokmer?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash"> Jingming Pan</a> on<a href="https://unsplash.com/photos/iYsrkq5qq0Q?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash"> Unsplash</a>

KWEB

Citigourp Global Markets 2% Protected Notes Linked To The Djia

As Israel-Palestine Conflict Escalates, Gold Ticks Up  - ETF Winners And Losers: Medium-Cap Returns

On <a href="https://www.cnbc.com/video/2021/06/16/your-question-your-trade-askhalftime.html">CNBC&#39;s &quot;Fast Money Halftime Report,&quot;</a> Joe Terranova said it&#39;s a good time to add Microsoft Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) to a portfolio. It&#39;s well positioned to grab market share in the cloud.
Jenny Harrington said if you prefer owning individual names, you should buy Medtronic PLC (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mdt#NYSE">MDT</a>) and if you want diversification, you should own iShares US Medical Devices ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ihi#NYSE">IHI</a>). You are going to make money in either case, she said.
Stephen Weiss said Jumia Technologies AG - ADR (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jmia#NYSE">JMIA</a>) and Vuzix Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vuzi#NASDAQ">VUZI</a>) stand an equal chance to pay off in five years. They&#39;re speculative so he would only put speculative money in them.
Jason Snipe said Paypal Holdings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pypl#NASDAQ">PYPL</a>) is a hold at this point.

JMIA

MSFT

PYPL

VUZI

'Halftime Report' Traders Share Their Thoughts On Microsoft, PayPal And More

On <a href="https://www.cnbc.com/video/2021/06/09/final-trades-american-express-clean-energy-t-mobile-more.html">CNBC&#39;s &quot;Fast Money Halftime Report,&quot;</a> Jim Cramer said T-Mobile Us Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmus#NASDAQ">TMUS</a>) is a rocket. He is a buyer of the stock.
Stephanie Link likes American Express Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/axp#NYSE">AXP</a>).
Jon Najarian bought Clean Energy Fuels Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clne#NASDAQ">CLNE</a>) during the show.
Joe Terranova wants to buy iShares US Medical Devices ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ihi#NYSE">IHI</a>).

CLNE

TMUS

'Fast Money Halftime Report' Picks For June 9

On CNBC&#39;s &quot;Fast Money Halftime Report,&quot;&nbsp;the investment committee gave their final trades of the day.
Gilman Hill Asset Management CEO Jenny Harrington likes ViacomCBS Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/viac#NASDAQ">VIAC</a>).&nbsp;
Chevy Chase Trust&#39;s Amy Raskin likes ASML Holding N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asml#NASDAQ">ASML</a>).
Market Rebellion Co-Founder Pete Najarian likes First Solar, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fslr#NASDAQ">FSLR</a>).
Virtus Investment Partners&rsquo; Joe Terranova likes iShares U.S. Medical Devices ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ihi#NYSE">IHI</a>).

ASML

FSLR

VIAC

'Halftime Report' Final Trades: ViacomCBS, First Solar And More

On CNBC&#39;s &quot;Fast Money Halftime Report,&quot; the investment committee gave their final trades of the day.
Market Rebellion Co-Founder Pete Najarian likes Medtronic plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mdt#NYSE">MDT</a>) and believes there is a lot of upside in the second half of 2021.
Requisite Capital Management Bryn Talkington likes Norwegian Cruise Line Holdings Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nclh#NYSE">NCLH</a>) and believes there is a lot of upside as more people get vaccinated.
Decatur Capital Management CEO Degas Wright likes Hanesbrands Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hbi#NYSE">HBI</a>) and notes the stock has a 3% dividend yield and is doing amazing through online sales.
Virtus Investment Partners&rsquo; Joe Terranova likes iShares U.S. Medical Devices ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ihi#NYSE">IHI</a>).

NCLH

'Halftime Report' Final Trades: Norwegian Cruise Lines, Medtronic And More

On <a href="https://www.cnbc.com/video/2019/12/06/is-adobe-a-buy-will-disney-stay-strong-traders-answer-your-questions.html">CNBC&#39;s &quot;Fast Money Halftime Report,&quot;</a> Joe Terranova said there&#39;s more room on the upside for iShares Dow Jones US Medical Dev. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ihi#NYSE">IHI</a>). He added that this is a secular play on aging population.
Margaret Reid said she likes Medtronic PLC (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mdt#NYSE">MDT</a>) going into the next year. She also likes Walt Disney Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dis#NYSE">DIS</a>).
Stephen Weiss bought Adobe Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adbe#NASDAQ">ADBE</a>) a couple of months ago. He thinks it is not cheap but expects the subscription revenue to grow.
Liz Young believes the Fed is not going to make a move in 2020.
Josh Brown thinks there are no technical signals that indicate Shake Shack Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/shak#NYSE">SHAK</a>) has bottomed. He owns it as an investor, but for a trade, he wouldn&#39;t get bullish again unless it trades above $69 or $70 level.

ADBE

SHAK

'Fast Money Halftime Report' Traders Weigh In On Adobe, Shake Shack And More

On <a href="https://www.cnbc.com/video/2019/11/25/final-trades-apollo-global-uber-european-equities-more.html">CNBC&#39;s &quot;Fast Money Halftime Report,&quot;</a> Mario Gabelli recommended a long position in Energizer Holdings Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/enr#NYSE">ENR</a>).
Pete Najarian noticed some call options activity in Apollo Global Management Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/apo#NYSE">APO</a>). He thinks the stock is going higher.
Jon Najarian is a buyer of Bed Bath &amp; Beyond Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bbby#NASDAQ">BBBY</a>).
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/19/11/14878180/kara-swisher-its-not-a-great-time-for-ubers-ceo">Kara Swisher: It&#39;s &#39;Not A Great Time&#39; For Uber&#39;s CEO</a>
Kourtney Gibson wants to buy Uber Technologies Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uber#NYSE">UBER</a>) on the dip.
Liz Young believes iShares S&amp;P Europe 350 Index (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iev#NYSE">IEV</a>) is a buy.
Joe Terranova likes iShares Dow Jones US Medical Dev. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ihi#NYSE">IHI</a>).

BBBY

UBER

Apollo Global, Uber And More 'Fast Money Halftime Report' Picks From Nov. 25

On <a href="https://www.cnbc.com/video/2019/10/23/final-trades-jj-mastercard-salesforce-and-more.html">CNBC&#39;s &quot;Fast Money Halftime Report,&quot;</a> Stephanie Link said she bought more shares in Johnson &amp; Johnson (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>) after it traded lower. She thinks fundamentals are very strong.
Pete Najarian is bullish on Mastercard Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ma#NYSE">MA</a>) because he noticed some call options buying. He also likes Visa Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/v#NYSE">V</a>).
Jon Najarian noticed short-term call options activity in salesforce.com, inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crm#NYSE">CRM</a>). He likes the stock and he wants to buy it.
Joe Terranova would buy iShares Dow Jones US Medical Dev. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ihi#NYSE">IHI</a>). He wants more exposure to the medical devices sector.

'Fast Money Halftime Report' Picks From October 23

Even with the benefit of Wednesday&#39;s rally, the S&amp;P 500 is still down about 8 percent this year. With just three trading days left in 2018, the S&amp;P 500 will need a couple of sequels to Wednesday if the benchmark U.S. equity gauge is to close the year in the green.
Of course, equity market struggles are hampering a broad swath of the U.S. universe of exchange traded funds. As of Dec. 26, just 69 U.S.-listed ETFs sported&nbsp;year-to-date gains of at least 10 percent and a significant portion of that group are leveraged funds, <a href="https://www.benzinga.com/trading-ideas/long-ideas/18/12/12897346/flight-to-safety-lifts-this-leveraged-etf">which aren&#39;t designed</a> to be buy-and-hold instruments.
Still, some traditional, pure beta ETFs are shining bright in 2018. Here are five of this year&#39;s best.
iShares U.S. Medical Devices ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ihi#NYSE">IHI</a>)
Year-To-Date Gain: 11.27 percent
The health care sector, the second-largest sector weight in the S&amp;P 500, is clinging to its status as 2018&#39;s best-performing sector and the iShares U.S. Medical Devices ETF is one of the leading ETFs in this group. Following a Wednesday gain of more than 5 percent, IHI is up more than 11 percent year-to-date. IHI, which tracks the Dow Jones U.S. Select Medical Equipment Index, is the largest medical devices ETF.
IHI is led by Abbott Laboratories (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abt#NYSE">ABT</a>) and Medtronic Plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mdt#NYSE">MDT</a>) and the fund is closing in on its fourth consecutive year of outperforming the S&amp;P 500 Health Care Index.
<a href="https://www.benzinga.com/news/18/12/12901723/5-worst-etfs-of-2018">Click here to read about the worst ETFs of the year.</a>
Invesco Dynamic Software ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/psj#NYSE">PSJ</a>)
YTD Gain: 13.73 percent
As has been widely documented, technology stocks have been among the worst offenders during the recent market swoon. Fortunately for the Invesco Dynamic Software ETF, the fund built up impressive gains earlier this year and never turned negative on a year-to-date basis during the fourth-quarter broader market slide.
Wednesday&#39;s 5.72 percent gain on almost quadruple the average daily volume helped PSJ, at least for one day, inch out of a bear market, but the fund is still 19 percent below its 52-week high.
PSJ components are evaluated on price momentum, earnings momentum, quality, management action, and value, <a href="https://www.invesco.com/portal/site/us/financial-professional/etfs/product-detail?productId=PSJ">according to Invesco</a>.
Aberdeen Standard Physical Palladium Shares ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pall#NYSE">PALL</a>)
YTD Gain: 16.2 percent
Despite the dollar being strong this year, a scenario hampering scores of commodities ETFs, the Aberdeen Standard Physical Palladium Shares ETF recently surged to record highs. The metal&#39;s recent surge has its prices flirting with those of gold, which is noteworthy because palladium usually trades at steep discounts to bullion.
Palladium&#39;s 2018 rally is the quintessential bullish commodities story: supply is not keeping up with demand.
&ldquo;Usage is increasing as governments, especially China&rsquo;s, tighten regulations to crack down on pollution from vehicles, forcing carmakers to increase the amount of precious metal they use,&rdquo; <a href="https://www.washingtonpost.com/business/why-palladiums-suddenly-an-especially-precious-metal/2018/12/20/3c08e27e-04b6-11e9-958c-0a601226ff6b_story.html">according to Bloomberg</a>. &ldquo;In Europe, consumers bought fewer diesel vehicles, which mostly use platinum, and instead chose gasoline-powered vehicles, which use palladium, following revelations that makers of diesel cars cheated on emissions tests.&rdquo;
iShares MSCI Qatar ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qat#NASDAQ">QAT</a>)
YTD Gain: 16.36 percent
In a year of struggles for emerging markets stocks and ETFs, the iShares MSCI Qatar ETF really stands out. The only ETF dedicated to stocks in Qatar is up more than 16 percent while the MSCI Emerging Markets Index is saddled with a year-to-date loss.
As a member of the Organization of Petroleum Exporting Countries, Qatar should be vulnerable to oil declines, but QAT is proving otherwise this year. Qatar is leaving OPEC next year to focus on natural gas production and exports.
United States Natural Gas Fund (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ung#NYSE">UNG</a>)
YTD Gain: 21.05 percent
Speaking of natural gas, the United States Natural Gas Fund is one of this year&#39;s best-performing non-leveraged ETFs, but most of those gains were accrued in November and a significant portion of those gains have been given back this month. Underscoring the volatile nature of trading natural gas, even with an ETF, UNG is up 21.05 percent this year but down more than<a href="https://finviz.com/quote.ashx?t=UNG&amp;ty=c&amp;ta=1&amp;p=d"> 22 percent in December</a>.

Short Ideas

Emerging Markets

Emerging Market ETFs

PALL

PowerShares ETF Tst Dynamic Software Portfolio

5 Best ETFs Of 2018

As has been widely documented, the healthcare sector, the S&amp;P 500&#39;s third-largest sector weight, is struggling this year. The Health Care SPDR (ETF) (NYSE: <a class="ticker" href="/stock/xlv#NYSE">XLV</a>), the largest healthcare exchange-traded fund by assets, is down nearly 4 percent this year and is in position to notch its first annual decline since 2008.
There have been pockets of strength with the healthcare sector, notably from healthcare equipment and medical device manufacturers. Just look at the SPDR Series Trust (NYSE: <a class="ticker" href="/stock/xhe#NYSE">XHE</a>). XHE is up nearly 12 percent year-to-date, making it this year&#39;s best-performing non-leveraged healthcare ETF.
<h3>XHE Vs. IHI</h3>
XHE holds 71 stocks with a weighted average market value of $10.6 billion, putting the ETF squarely in mid-cap territory. That makes XHE significantly different than its chief competitor, the iShares Dow Jones US Medical Dev.(ETF) (NYSE: <a class="ticker" href="/stock/ihi#NYSE">IHI</a>), which holds 52 stocks. IHI is a cap-weighted fund, while XHE uses an equal-weight methodology.
Not surprisingly, that leads to diverging returns, as XHE is outpacing IHI by more than 200 basis points this year. Over the past three years, XHE has trailed IHI while being slightly more volatile. About 74.5 percent of XHE&#39;s holdings are considered healthcare equipment makers while the remainder of the ETF&#39;s lineup is classified as <a href="https://us.spdrs.com/en/product/fund.seam?ticker=XHE"> makers of healthcare supplies</a>.
<h3>Politics And Healthcare</h3>
As has been duly noted throughout the course of this presidential election, rhetoric from both parties concerning high pharmaceuticals prices has been a drag on the healthcare sector and for biotechnology stocks in particular.
Unfortunately, healthcare leaders have recently retreated. For example, medical device makers have been the strongest part of the healthcare sector this year, but have recently tumbled. XLV allocates over <a href="https://www.spdrs.com/">23 percent of its weight</a> to healthcare equipment makers and life sciences tools manufacturers.
Politics are also at play for ETFs such as XHE and IHI, but in a more positive way.
&ldquo;&ldquo;When the Affordable Care Act (ACA), also known as Obamacare, was passed in 2010, the legislation include a tax on medical device companies, including those found in IHI. It is widely expected that the Trump Administration will work to repeal that tax and do swiftly,&rdquo; according to <a href="http://investorplace.com/2016/12/healthcare-etfs-bounce-back-ihi-cncr-pth/2/#.WFnj233573B">InvestorPlace</a>.

Politics

Meet This Year's Best Healthcare ETF

Ahead of Election Day, &quot;Shark Tank&quot; investor Kevin O&#39;Leary shared a preview of a few trades he was considering in case Donald Trump <a href="http://www.benzinga.com/general/education/16/11/8654498/gamblers-are-hedging-their-election-bets-but-clinton-remains-heavy-f">wins the presidency</a>.

	O&#39;Leary&#39;s strategy centers around a big boost to biotech stocks given Democratic rhetoric towards the sector in the election cycle.

	Throughout the Democratic primary and general election, nominee Hillary Clinton and primary challenger Sen. Bernie Sanders frequently criticized biotech companies for increases in drug prices. Congressional hearings in recent years have found fault with price increases in the hundreds of percentage points from companies like Valeant Pharmaceuticals Intl Inc (NYSE: <a class="ticker" href="/stock/vrx#NYSE">VRX</a>) and Mylan NV (NASDAQ: <a class="ticker" href="/stock/myl#NASDAQ">MYL</a>).

	&ldquo;If you thought Trump was going to win and you&#39;re doing thematic trading, what interests me would be the healthcare sector: biotech, generics, large pharma domestic and medical devices companies,&rdquo; O&#39;Leary told Benzinga in an interview.

	O&rsquo;Leary thinks investors can take advantage of the pressure Democrats have put on the biotech sector in case of a Trump win, which he believes <a href="http://www.benzinga.com/general/politics/16/11/8651901/why-kevin-oleary-thinks-trump-could-still-win">is more likely</a> than polls suggest.

	&ldquo;I think you go long for every dollar you put 25 cents into IHI (iShares U.S. Medical Devices ETF (AMEX: IHI)), PJP (PowerShares Dynamic Pharmaceuticals (AMEX: PJP)), IBB (iShares Nasdaq Biotechnology Index Fund (NASDAQ: <a class="ticker" href="/stock/ibb#NASDAQ">IBB</a>)), JRX,&rdquo; O&#39;Leary said. &ldquo;They have had the living stuffing kicked out of them. Bernie Sanders did another number on pharma, [and the sector&rsquo;s] down another 100 basis points. This rhetoric is really compressing PEs. That&rsquo;s a trade I will probably put on, because I the data I&rsquo;ve seen on the polling tells me I have a 50/50 chance of Trump. If I end up being wrong anyways, I&rsquo;m buying at a material discount and extremely high yields past 3%. That&rsquo;s one way to go through next week and probably thematic trade for the next quarter,&rdquo; O&#39;Leary concluded.

	On November 18, O&#39;Leary will be sharing his 2017 investment outlook at the CFA Society of Detroit&#39;s Annual Forecast Luncheon. <a href="http://www.cfasociety.org/detroit/Lists/Events%20Calendar/DispForm.aspx?ID=322&amp;Source=https%3A%2F%2Fwww%2Ecfasociety%2Eorg%2Fdetroit%2Flists%2Fevents%2520calendar%2Fcalendar%2Easpx">See here</a> for more information.&ensp;

Interview

Mr. Wonderful's Election Week Trades For A Trump Victory

Radio frequencies frequently emitted by cellphones can cause cancer, according to partial findings of a government study on rats, reported the <a href="http://www.wsj.com/articles/cellphone-cancer-link-found-in-government-study-1464324146">Wall Street Journal</a>.
The National Toxicology Program (NTP) has carried out extensive toxicology and carcinogenesis <a href="http://biorxiv.org/content/early/2016/05/26/055699.full.pdf">studies of radiofrequency radiation (RFR)</a> in rats over multiple years. The studies involved observing the effects of frequencies and modulations found in the U.S. telecommunications industry on the rodents, paying particular attention to the potential of cancer-cell developments.
<h3>The Study</h3>
The peer-reviewed study found "the occurrences of two tumor types in male Harlan Sprague Dawley rats exposed to RFR (radiofrequency radiation), malignant gliomas in the brain and schwannomas of the heart," according to <a href="http://www.nbcnews.com/health/health-news/possible-cellphone-link-cancer-rat-study-launches-new-debate-n581621">the research team</a>.
<bzrelatedlink>Related Link: <a href="http://www.benzinga.com/news/16/05/8040684/astrazeneca-remains-committed-to-development-of-zs-9-despite-letter-from-fda">AstraZeneca Remains Committed To Development of ZS-9 Despite Letter From FDA</a></bzrelatedlink>
"Given the widespread global usage of mobile communications among users of all ages, even a very small increase in the incidence of disease resulting from exposure to [radio-frequency radiation] could have broad implications for public health," the <a href="http://www.wsj.com/articles/cellphone-cancer-link-found-in-government-study-1464324146">Wall Street Journal</a> quoted a report of partial findings from the study.
Under these studies, rats and mice were exposed to radio-frequency "with two signal modulations [Code Division Multiple Access (CDMA) and Global System for Mobile Communications (GSM)] at two frequencies (900 MHz for rats and 1900 MHz for mice)," the <a href="http://biorxiv.org/content/biorxiv/early/2016/05/26/055699.full.pdf">NTP</a> wrote.
The study also found that "the tumors in the brain and heart observed at low incidence in male rats exposed to GSM and CDMA-modulated cell phone RFR in this study are of a type similar to tumors observed in some epidemiology studies of cell phone use."
"All RF exposures were conducted over a period of approximately 18 hours using a continuous cycle of 10 minutes on (exposed) and 10 minutes off (not exposed), for a total daily exposure time of approximately 9 hours a day, 7 days/week," according to the study.
<h3>What Does It All Mean?</h3>
"Where people were saying there's no risk, I think this ends that kind of statement," the <a href="http://www.wsj.com/articles/cellphone-cancer-link-found-in-government-study-1464324146">Wall Street Journal</a> report said, quoting Ron Melnick, who ran the NTP project until his retirement in 2009.
The Journal said, "It's not clear how the results may impact the government's cellphone safety recommendations."
"Scientific evidence always informs FCC rules on this matter," an FCC spokesman told the Journal. "We will continue to follow all recommendations from federal health and safety experts including whether the FCC should modify its current policies and RF exposure limits."

Comments

iShares U.S. Medical Devices ETF

ニュース

最新ニュース iShares U.S. Medical Devices ETF (ARCA:IHI)

ニュース

パートナーシップ

ベンジンガ・グローバル